Board Member
Palvella Therapeutics, Inc. (PVLA)Equibles does not estimate personal net worth.
Get an email with a short summary when Palvella Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get PVLA alertsWesley H. Kaupinen is recorded as Board Member and CEO at Palvella Therapeutics, Inc. (PVLA). The newest filing on record that lists Wesley H. Kaupinen as Board Member and CEO at Palvella Therapeutics, Inc. (PVLA) is dated April 30, 2026. Palvella Therapeutics, Inc. reported in an 8-K filed December 16, 2024 that Wesley H. Kaupinen was appointed Chief Executive Officer, Founder, President and Director, effective December 13, 2024. Palvella Therapeutics, Inc. reported in an 8-K filed December 16, 2024 that Wesley H. Kaupinen was appointed Director, effective December 13, 2024. Wesley H. Kaupinen has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Palvella Therapeutics, Inc. on August 12, 2026. Palvella Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Palvella Therapeutics, Inc. includes George M. Jenkins (Chairman and Board Member), James Geraghty (Chairman), Matthew E. Korenberg (CFO) and 7 others.
“In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers and directors of the Company: Wesley H. Kaupinen | 47 | Chief Executive Officer, Founder, President and Director”
“At the Effective Time, Wesley H. Kaupinen, George M. Jenkins, Todd C. Davis and Tadd S. Wessel were each appointed to serve as a director of the Company.”
“This is our second year in a row having the opportunity to present at the Canaccord Conference. Appreciate your coverage. You were one of the first analysts to initiate coverage on Pelvella after we went public.”
“I am speaking to you today alongside our passionate management team, whose dedication and execution have helped bring our company to what we believe is a major inflection point.”
Start not stated–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
Board Member, CEO
